Autres langues ACADIA Pharmaceuticals Inc.

Actions

ACAD

US0042251084

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 24/09/2026			Varia. 5j.	Varia. 1 janv.
22,18 ^USD	-12,78%		-19,20%	-16,96%

14:04	ACADIA Pharmaceuticals Inc. : Deutsche Bank Securities maintient sa recommandation à l'achat	ZM
24/09	Transcript : ACADIA Pharmaceuticals Inc. - Special Call

Autres langues

24/09	Sector Update: Healthcare Stocks Advance Late Afternoon
24/09	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions Before US-China Talks
24/09	Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
24/09	Acadia Pharmaceuticals Inc. Announces Phase 3 Enabling Topline Results from Phase 2 Radiant Study of Remlifanserin for the Treatment of Alzheimer?S Disease Psychosis
24/09	ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint
24/09	Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
25/08	EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu
25/08	Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug
24/08	Acadia Pharmaceuticals Inc. Receives European Commission Approval For DAYBU For Treatment Of Neurobehavioral Symptoms Of Rett Syndrome
24/08	ACADIA Pharmaceuticals Wins EU Approval for Rett Syndrome's Drug
24/08	European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
24/08	La Comisión Europea aprueba DAYBU® (trofinetida) como el primer y único tratamiento para los síntomas neuroconductuales del Síndrome de Rett en la Unión Europea
24/08	De Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie
24/08	Europäische Kommission erteilt Zulassung für DAYBU® (Trofinetid) als erste und einzige Therapie für neurobehaviorale Symptome des Rett-Syndroms in der Europäischen Union
10/08	Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says
05/08	ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says
05/08	Neuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%
04/08	ACADIA Pharmaceuticals Q2 Earnings, Revenue Rise; Lifts 2026 Outlook
04/08	Earnings Flash (ACAD) ACADIA Pharmaceuticals Posts Q2 EPS $0.18, vs. FactSet Est of $0.06
04/08	Earnings Flash (ACAD) Acadia Pharmaceuticals Inc. Reports Q2 Revenue $308.0M, vs. FactSet Est of $295.5M
04/08	Acadia: Q2 Earnings Snapshot
04/08	Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
04/08	Acadia Pharmaceuticals Inc. Increases Earnings Guidance for the Fiscal Year 2026
04/08	ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/07	Acadia Pharmaceuticals Inc. Receives FDA Fast Track Designation for Remlifanserin in Alzheimer?S Disease Psychosis